{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.9","upperLimit":"59.9","value":"33.3"},{"groupId":"OG001","lowerLimit":"40.4","upperLimit":"92.1","value":"71.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Percentage of patients who have CR, PR, or SD lasting ≥ 8 weeks. Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.","dispersionType":"80% Confidence Interval","groups":[{"description":"Assigned to 60 mg dose, 6 doses/cycle","id":"OG000","title":"Selinexor (PTCL)"},{"description":"Assigned to 60 mg dose, 6 doses/cycle (6 patients); Assigned to 60 mg dose, 8 doses/cycle (1 patient)","id":"OG001","title":"Selinexor (CTCL)"}],"paramType":"NUMBER","populationDescription":"Intent to Treat (ITT) Population","reportingStatus":"POSTED","timeFrame":"Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}